The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC ...

FL represents roughly 20% to 30% of all non-Hodgkin lymphoma diagnoses, with approximately 14,000 new cases diagnosed in the US annually. | Image credit: wladimir1804 - stock.adobe.com ...

Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo ...

Session ID: 2025-07-01:c3d96494478f7322ba15e67b Player Element ID: Vd5cd1b33_dfb7_4cb6_a47a_a289603d2ac9_6374240200112 ...

Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo ...

IDeate-Prostate01 is a multicenter, open-label, randomized phase 3 trial evaluating the safety and efficacy of ifinatamab deruxtecan (12 mg/kg) versus docetaxel (75 mg/m 2) plus corticosteroid in ...

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with ...

Key Takeaways The IDeate-Prostate01 trial compares ifinatamab deruxtecan to docetaxel in mCRPC patients with prior ARPI treatment failure. Approximately 1440 patients will be enrolled globally, ...

AP IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer Business Wire Jun 18, 2025 Updated Jun 18, 2025 ...